Replies to post #29280 on Amarin Corp Plc (AMRN)

[alternatepatel]

Can Improve-IT results affect ANCHOR?

"..In March 2013, the Data Safety Monitoring Board (the “DSMB”) of the IMPROVE-IT trial, a large cardiovascular outcomes study evaluating ezetimibe/simvastatin against simvastatin alone in patients presenting with acute coronary syndrome, completed its planned review of study data and recommended that the study continue. Merck remains blinded to the actual results of this analysis and to other IMPROVE-IT safety and efficacy data. IMPROVE-IT is an 18,000 patient event-driven trial and, based on the targeted number of 5,250 clinical endpoints and the rate at which events are being reported, the trial is projected to conclude later in 2014. If the results of the IMPROVE-IT trial fail to demonstrate an incremental benefit of ezetimibe/simvastatin on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin, sales of Zetia and Vytorin could be materially adversely affected and, if so, the Company may take non-cash impairment charges with respect to the carrying values of the Zetia and Vytorin intangible assets, which were $4.4 billion and $2.5 billion, respectively, at March 31, 2014 and such charges could be material.."

[jessellivermore]

Chica..

Dr. Libby of the Brigham in Boston paints a beautiful picture of the inflammatory nature of atheroscerotic heart disease (AHD), but tragically there is an immense gaping hole in his knowledge of the disease.

If the cause of AHD is compared to the "Creationists vs the Evolutionists, with the lipidologist being the creationists, and the inflammationists being the evolutionists, then Dr. Libby is trying to rationalise evolution (inflammation) in terms of creation.

Dr. Libby argues that the thirty year siege on what constitutes healthy cholesterol levels which he feels now should be LDL-C levels under 100 (down from 300), are a failure on the part of doctors to understand just how bad LDL-C really is. As such, he is a "Statinista," firmly in the creation camp.

Furthermore he blindly rationalizes the fact that the LDL-C figures do not jive with the clinical reality that over 50% 0f heart attacks come with "normal" LDL-Cs; by saying that minor infections raise systemic inflammation which tips the boat. He must think populations like the Japanese, which have low AHD, do not get colds or viruses.

It is clear the Dr. knows nothing about the eicosanoid system, or the anti-inflammatory effect of EPA in sufficient dosages.

":>) JL